Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 3, Issue 5, Pages 763-770Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2012.502
Keywords
diffuse large B-cell lymphoma; miR-155; miR-146a; diagnostic and prognostic marker
Categories
Funding
- Shanghai Municipal Commission of Sciences and Technology [09ZR1418400]
- Social Development fund of the Shanghai Pudong District [PW2009D-5]
- Renji Hospital, Shanghai Jiaotong University School of Medicine [RJ 4101306]
Ask authors/readers for more resources
It has been found that aberrant expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In the present study, we investigated the expression of miR-155 and miR-146a in diffuse large B-cell lymphoma (DLBCL) patients (n=90). The expression levels of miR-155 and miR-146a were significantly higher in de novo DLBCL patients. miR-146a expression levels were associated with miR-155, lactate dehydrogenase, beta 2 microglobulin, c-myc, International Prognostic Index status and Eastern Cooperative Oncology Group performance status. We found that with low miR-155 and miR-146a expression levels achieved a higher complete remission rate, higher overall response rate and longer progression-free survival time. Moreover, a high expression level of miR-155, but not miR-146a, was an independent indicator for chemotherapy protocol selection in our study. Patients with high expression of miR-155 received more survival benefits from rituximab treatment. These data suggest that miR-155 and miR-146a have potential as diagnostic and prognostic markers in :DLBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available